Fischer Medical Ventures Issues Corrigendum for FY26 Annual Report, Correcting Key Financial and Auditor Details
Fischer Medical Ventures Limited issued a corrigendum for its FY 2025-26 Annual Report, correcting errors in financial highlights, auditor's reports, equity share capital, and financial tables. The updated report addresses discrepancies on pages 70, 136, 182, 147, 193, 171, 173, 220, and 222. The original report was dispatched on September 7th, 2026.
This is a routine correction of errors in an annual report and does not materially affect the company's business operations, financial performance, or future outlook.
The announcement is a corrigendum, rectifying errors in a previously issued report. While it aims to improve accuracy, it does not introduce new positive or negative business developments.
Fischer Medical Ventures Limited has issued a corrigendum to its Annual Report for the financial year 2025-26. This update addresses several inadvertent errors and omissions to ensure accuracy in the reported financial and operational information.
Key corrections have been made across various pages of the annual report. Specifically, on page 70, minor errors in the 'Financial Highlights and Key Financial Ratios' section have been rectified. The Independent Standalone and Consolidated Auditor’s Reports on pages 136 and 182, respectively, have been updated with the correct Unique Document Identification Number (UDIN).
Further adjustments include corrections to the Paid-up Equity Share Capital on page 147 (Standalone) and page 193 (Consolidated) within the Profit and Loss Statements. The company has also revised the 'Maturity Analysis of Assets and Liabilities' table in the Standalone Financials (Note 32, page 171) for presentation purposes. Additionally, prior year numbers in the 'Capital Management' table (Note 32, page 173) and updates to the 'Foreign Currency Exposure' table (Note 39, page 220) and 'Maturity Analysis of Financial Assets and Liabilities' table (Note 39, page 222) have been incorporated.
These corrections are being submitted along with the updated Annual Report for FY 2025-26. The company previously emailed and dispatched the original Annual Report and the Notice for the 33rd Annual General Meeting to its shareholders and stakeholders on September 7th, 2026.
What to do with a filing like this
Fischer Medical Ventures Limited filed this with the NSE as a statutory disclosure, categorised under other regulatory filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fischer Medical Ventures Limited. Read the original for the full detail.